5th Sep 2006 16:41
Stem Cell Sciences plc05 September 2006 For Immediate Release 5 September 2006 Stem Cell Sciences plc Notice of Interim Results Stem Cell Sciences plc, the global stem cell company focused on the application of stem cell technologies to cell culture media, cell based drug screens and novel cell therapies, will be announcing interim results for the six months ended 30 June 2006 on Friday 15 September 2006. - Ends- Enquiries Weber Shandwick Square Mile 020 7067 0700James White Notes to Editors: Stem cells are undifferentiated (unspecialised) cells that can divide to make copies of them selves or differentiate (change) to become specialised cells of aspecific tissue such as neural cells or blood cells. Stem Cell Sciences plc (SCS, AIM: STEM) is a global biotechnology company focused on the development and application of stem cell technologies in biopharmaceutical research and cell-based therapies. The Company hasestablished a leading intellectual property (IP) and technology portfolio that enables the commercial application of stem cells in pharmaceutical/ biotechnology drug discovery and development, providing the Company with an early-stage revenue stream. In the longer term, the Company is developing regenerative, cell-based therapies. SCS operates as a group of independent operations with laboratories in Scotland, Japan and Australia, each of which is affiliated with an academic centre of excellence. These include the Institute of Stem Cell Research, Edinburgh, UK; RIKEN Centre for Development Biology, Kobe, Japan and the Australian Stem Cell Centre, Melbourne, Australia. Stem Cell Sciences listed on the London AIM exchange on 18 July 2005 (AIM: STEM). This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
SThree